Mountaineer nct03043313
Nettet1. okt. 2024 · MOUNTAINEER is a multicenter open-label single-arm phase II trial. Pts with RAS WT mCRC had HER2 amplification/overexpression by NGS, FISH, or IHC (3+ or … NettetTucatinib is a highly selective, HER2-directed, tyrosine kinase inhibitor. The MOUNTAINEER trial (NCT03043313) was initiated to evaluate the efficacy and safety of the investigational combination of tucatinib with trastuzumab in patients with HER2+ mCRC. Here we present results from the primary analysis of MOUNTAINEER. Methods
Mountaineer nct03043313
Did you know?
NettetMOUNTAINEER is a multicenter open-label single-arm phase II trial. Pts with RAS WT mCRC had HER2 amplification/overexpression by NGS, FISH, or IHC (3+ or 2+ and amplified by FISH). Prior treatment with 5FU, oxaliplatin, irinotecan, and an anti-VEGF antibody was required. Prior anti-HER2 therapy was excluded. NettetThe primary analysis of MOUNTAINEER (NCT03043313) in cohorts A+B treated with tucatinib (TUC) + trastuzumab (Tras) was previously reported and showed tolerability and a confirmed objective response rate (cORR) per blinded independent central review (BICR) of 38.1%. Here, additional results of TUC monotherapy (cohort C) are reported. Methods
Nettet20. jan. 2024 · Based on these results, the trial was expanded to enable better estimation of ORR and safety. Methods: MOUNTAINEER (NCT03043313) is an open-label, pivotal phase 2 trial that initially consisted of a single cohort of up to 45 pts (Cohort A) treated with TUC (300 mg BID) and TRAS (8 mg/kg IV followed by 6 mg/kg IV every 3 weeks). NettetMOUNTAINEER is an open-label, pivotal phase II study that initially consisted of a single cohort of up to 45 pts (Cohort A) treated with TUC (300 mg BID) and TRAS (8 mg/kg IV followed by 6 mg/kg IV every 3 weeks).
Nettet20. apr. 2024 · In the phase 1b/2 MOUNTAINEER trial (NCT03043313), tucatinib is being evaluated as monotherapy and in combination with trastuzumab in patients with HER2 … Nettet25. jan. 2024 · Efficacy was evaluated in 84 patients in MOUNTAINEER (NCT03043313), an open-label, multicentre study. Patients were required to have HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer and prior treatment with fluoropyrimidine, oxaliplatin, irinotecan, and an anti-VEGF monoclonal antibody.
Nettet19. jan. 2024 · Approval of this chemotherapy-free combination is based on results from the phase 2 MOUNTAINEER trial ( NCT03043313 ), which found a 38% overall …
Nettet14. mai 2024 · MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer. lm weakness\u0027sNettetFROM THE MOUNTAINEER TRIAL Andrea Cercek,1 Kimmie Ng,2 John H. Strickler,3 Salvatore Siena,4 Thierry Andre, 5 Eric Van Cutsem,6 Christina Wu,7 Andrew Scott Paulson,8 Joleen M. Hubbard,9 Andrew L. Coveler,10 Christos Fountzilas,11 Adel Kardosh, 12 Pashtoon Murtaza Kasi,13 ... • The MOUNTAINEER trial (NCT03043313) ... india free tv channelNettetMOUNTAINEER (NCT03043313) is evaluating safety and efficacy of TUC and trastuzumab (Tras) in pts w/ tx refractory RAS wild-type, HER2+ mCRC; preliminary … india free numberNettet10. apr. 2024 · 此次Tukysa获得优先审批是基于代号为MOUNTAINEER的 2 期试验 (NCT03043313) 的临床结果。 值得一提的是，这是HER+结直肠癌获批的头款靶向治疗方案，对于行业以及广大患者都具有重要意义。 india free phone number for verificationNettetMOUNTAINEER: Tucatinib plus trastuzumab demonstrates good efficacy for the treatment of HER2-positive metastatic colorectal cancer. In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to approximately 52,580 deaths in 2024. Human epidermal growth factor receptor 2 (HER2) is … lm weasel\u0027sNettet24. mai 2024 · The MOUNTAINEER trail is a multicenter, open-label, phase 2 study using tucatinib as a single agent or in combination with trastazumab in 117 patients. The … indiafreenotes bba bangalore universityNettet2. feb. 2024 · Data from the phase 2 MOUNTAINEER (NCT03043313) trial supported the approval, which showed that at a median follow-up of 20.7 months, the combination elicited an overall response rate (ORR) of 38% ... indiafreestuff india